Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback